Mycobacterium tuberculosis (Mtb) establishes a persistent infection, despite inducing antigen-specific T-cell responses. Although T cells arrive at the site of infection, they do not provide sterilizing immunity. The molecular basis of how Mtb impairs T-cell function is not clear. Mtb has been reported to block major histocompatibility complex class II (MHC-II) antigen presentation; however, no bacterial effector or host-cell target mediating this effect has been identified. We recently found that Mtb EsxH, which is secreted by the Esx-3 type VII secretion system, directly inhibits the endosomal sorting complex required for transport (ESCRT) machinery. Here, we showed that ESCRT is required for optimal antigen processing; correspondingly, overexpression and loss-of-function studies demonstrated that EsxH inhibited the ability of macrophages and dendritic cells to activate Mtb antigen-specific CD4 + T cells. Compared with the wild-type strain, the esxH-deficient strain induced fivefold more antigen-specific CD4 + T-cell proliferation in the mediastinal lymph nodes of mice. We also found that EsxH undermined the ability of effector CD4 + T cells to recognize infected macrophages and clear Mtb. These results provide a molecular explanation for how Mtb impairs the adaptive immune response.
H ost defences, both innate and adaptive, are subverted by Mycobacterium tuberculosis (Mtb). During Mtb infection, there is a delay in priming antigen-specific CD4 + and CD8 + cells by dendritic cells (DCs) in the lymph node 1 . When the effector CD4 + T cells traffic to the site of infection in the lungs, although they promote the antimycobacterial activity of macrophages by secreting cytokines such as interferon (IFN)-γ 2 , they fail to generate sterilizing immunity. Currently, we lack a comprehensive and detailed understanding as to why major histocompatibility complex class II (MHC-II) antigen presentation fails during Mtb infection. In naive macrophages, Mtb can act through Toll-like receptor 2 to block IFN-γ-induced MHC-II transcription [3] [4] [5] , although the contribution this plays in vivo is unclear 6 . How Mtb impairs antigen presentation in macrophages already expressing MHC-II is less well understood. One proposed mechanism is that by blocking phagosome maturation Mtb impairs efficient processing of antigen and the MHC-II-associated invariant chain 7, 8 . However, there have been contradictory results regarding the impact of phagosome maturation on antigen presentation [8] [9] [10] [11] . Contradictory results have also been reported in DCs. Some studies have demonstrated that Mtb inhibits DCs maturation, thereby impairing mobilization of MHC-II molecules to the cell surface 12 , whereas others have shown that Mtb upregulates DC expression of MHC-II, co-stimulatory molecules and inflammatory cytokines 13, 14 . More recent data have shown that Mtb-infected DCs are inefficient at priming antigen-specific CD4 + T cells [15] [16] [17] . Rather, bystander uninfected cells take up Mtb antigen and prime CD4 + T cells 18, 19 . Our group recently found that Mtb EsxH inhibits phagosome maturation by targeting the host endosomal sorting complex required for transport (ESCRT) 20 . EsxH forms a heterodimer with EsxG (EsxGH Mt ), which is secreted by the Esx-3 type VII secretion system. EsxGH Mt is involved in iron and zinc acquisition [21] [22] [23] [24] [25] , and recent work has demonstrated that EsxGH Mt also plays an additional role in virulence 20, 26, 27 . EsxGH Mt binds the host protein hepatocyte growth factor-regulated tyrosine kinase substrate (HGS, also known as HRS), a component of the ESCRT machinery 20 . ESCRT plays a well-described role in directing cell-surface receptors into intraluminal vesicles of multivesicular bodies so they can be degraded in the lysosome 28 . We found that ESCRT is also required for phagosome maturation 20, 29 , and we hypothesized that ESCRT, and by extension EsxGH Mt , regulates MHC-II antigen presentation. In this study, we showed that ESCRT promotes T-cell activation during Mtb infection by facilitating antigen processing. We demonstrated that EsxGH Mt impairs the ability of macrophages and DCs to present mycobacterial antigens and activate CD4 + T cells, resulting in impaired T-cell priming and defective effector function. Overall, our data support a model in which EsxH inhibits ESCRT, thereby undermining two key aspects of the adaptive immune response: (1) efficient priming of naive T cells, and (2) recognition of Mtb-infected cells by CD4 + T cells.
with Mtb-infected BMDMs. We found that macrophages depleted of HRS or TSG101 were poor at stimulating P25TCR-Tg effector CD4 + T cells, inducing 30% less IFN-γ release than control cells (Fig. 1b) . Similar findings were observed with CD4 + T H 1 cells specific for another prominent secreted antigen of Mtb, EsxA/ESAT-6 3-15 (C7TCR-Tg T H 1 cells; Fig. 1c ). IFN-γ production by P25 and C7 TCR T H 1 cells was antigen specific, as IFN-γ was not made following co-culture with macrophages infected with Ag85B-or ESAT-6-null strains of Mtb (ΔfpbB and ΔesxA; Fig. 1b,c) . Importantly, multiple independent small interfering RNAs (siRNA) targeting Tsg101 or Hrs impaired the ability of infected macrophages to stimulate T cells ( Supplementary Fig. 1a-c) , and the degree of HRS depletion correlated with levels of impairment in T-cell activation ( Supplementary Fig. 1b,c) . At the maximal HRS depletion that we were able to achieve, approximately 20% of HRS protein remained, and IFN-γ production was suppressed by approximately 40%. These results indicated that ESCRT promotes the ability of macrophages to activate Mtb-specific CD4 + effector T cells.
ESCRT facilitates antigen processing by macrophages. The role of ESCRT in antigen presentation has not been studied. In DCs, cellsurface levels of MHC-II are regulated by ubiquitin-dependent sorting to lysosomes 31, 32 , suggesting that ESCRT might control MHC-II trafficking in DCs, although this has not been tested directly. Whether ESCRT would play a similar role in BMDMs is unclear. To assess this directly, we compared cell-surface MHC-II levels between control BMDMs and those depleted of HRS or TSG101. We found no difference, regardless of infection status, when assayed by flow cytometry (Fig. 2a) . It is also possible that, by controlling the multivesicular architecture of the MHC-II compartment or promoting phagosome maturation 20, 29 , ESCRT might influence antigen processing or loading. We found that ESCRT-depleted BMDMs were impaired for activating P25TCR-Tg CD4 + effector T cells in the presence of exogenously added recombinant Ag85B, but behaved similarly to controls when peptide 25 was used as the antigen (Fig. 2b) , suggesting that the defect is at the level of processing the protein into peptide. To evaluate this further, we used DQ-OVA, a self-quenched conjugate of ovalbumin that exhibits bright green fluorescence on proteolytic degradation (Fig. 2c) . Quantification of fluorescence indicated that ESCRT silencing impaired the degradation of ovalbumin (Fig. 2d) . From these experiments, we concluded that ESCRT promotes antigen presentation by facilitating antigen processing.
ESCRT does not restrict bacterial growth in IFN-γ-activated macrophages. Although Mtb arrests phagosome maturation, in naive macrophages a fraction of the bacilli are delivered to the lysosome, which we previously showed depends on ESCRT 20 . As IFN-γ partially overcomes the arrest in phagosome maturation imposed by Mtb [33] [34] [35] , we asked whether ESCRT is also involved in phagosome maturation in IFN-γ-activated macrophages, which we used for the antigen presentation assays. As we reported previously, silencing of Tsg101 and Hrs in naive macrophages did not decrease the total lysosomal-associated membrane protein 1 (LAMP1) signal but led to diminished co-localization between Mtb and LAMP1 (a marker of late endosomes and lysosomes) and enhanced intracellular bacterial growth when compared with control cells (Supplementary Fig. 2a,c,d ) 20 . Surprisingly, in IFN-γ-activated macrophages, the same silencing had no effect on the co-localization of bacteria with LAMP1 or on bacterial survival ( Supplementary Fig. 2b-d) . Thus, phagolysosomal maturation and control of Mtb replication is largely independent of ESCRT in IFN-γ-activated macrophages. Therefore, the impairment in antigen presentation seen with ESCRT silencing is not due to an overall difference in bacterial degradation.
Antigen presentation is impaired by Mtb EsxGH Mt but not by Mycobacterium smegmatis EsxGH. As EsxGH Mt disrupts ESCRT 20 , we wondered whether EsxGH Mt impairs antigen presentation. We found that macrophages infected with a ΔesxH mutant elicited 50% more T-cell activation compared with BMDMs infected with wild-type Mtb, as assessed by IFN-γ production (Fig. 3a) . Bone marrow-derived DCs (BMDCs) showed an even more pronounced effect, as infection with the ΔesxH mutant resulted in a greater than threefold enhancement in T-cell activation (Fig. 3b) . In both cases, the increase in T-cell activation was largely reversed by genetic complementation. The enhanced response was not due to more Ag85B secretion from the mutant (Fig. 3c) . While the ΔesxH mutant requires exogenous siderophore to grow on solid medium, it is only modestly impaired in liquid medium 26 , and there was no difference in the intracellular survival of the wild type and ΔesxH at the time the antigen presentation assay was performed (Fig. 3d) . Furthermore, when ESCRT was silenced, the ΔesxH mutant stimulated P25 T cells to a similar extent as control cells infected with wild-type Mtb (Fig. 3e) + T cells compared with those infected with a strain containing the vector (Fig. 3f) . In addition, when Mtb contained a plasmid bearing EsxGH Ms , the M. smegmatis homologue of EsxGH Mt , which does not inhibit ESCRT 20 , there was no effect on antigen presentation (Fig. 3f) . The degree of inhibition was comparable if Mtb overexpressed EsxGH Mt or if ESCRT was silenced in the BMDMs (Fig. 3g) . Infecting ESCRT-depleted macrophages with the Mtb strain overexpressing EsxGH Mt did not result in an additive defect in T-cell activation beyond that seen with either manipulation alone. This is consistent with the idea that EsxGH Mt and siRNAs depleting HRS and TSG101 target a common pathway required for antigen presentation. In cells in which Tsg101 or Hrs were silenced, there was no statistically significant difference in T-cell activation between infection with the vector control strain and the overexpressing strain, although there was a trend towards a small decrease from the overexpressing strain. In macrophages infected by Mtb overexpressing EsxGH Mt , Hrs silencing resulted in a small but statistically significant decrease in IFN-γ production relative to macrophages treated with control siRNA. These small decreases associated with the combination of the overexpressing strain and ESCRT silencing might be because RNAi-mediated silencing and EsxGH Mt do not fully inhibit Hrs or because EsxGH Mt has additional targets. Overall, we concluded that both overexpression and loss-of-function studies indicated that EsxGH Mt impairs effector T-cell responses, similar to the situation seen with ESCRT silencing.
Antigen presentation is unaffected by PE5 and EsxA. In addition to containing esxG and esxH, the esx-3 locus encodes pe5 and ppe4, members of the proline-glutamic acid (PE) and proline-prolineglutamic acid (PPE) families, respectively. Tufariello et al. 26 showed that PE5 is secreted by Esx-3, and, like the ΔesxH mutant, Δpe5-ppe4 requires exogenous siderophore-bound iron to grow on solid medium. In addition, the ΔesxH mutant fails to secrete PE5, raising the possibility that PE5 is responsible for the phenotype of the ΔesxH mutant. However, unlike ΔesxH, the Δpe5-ppe4 mutant did not result in increased T-cell responses (Fig. 3a,b) . Thus, the influence of EsxH on antigen presentation is not explained by its role in iron acquisition or its effect on PE5 secretion. We also tested the role of EsxA, which is secreted by the Esx-1 type VII secretion system. Macrophages and DCs infected with the ΔesxA mutant did not showed increased ability to activate T cells (Fig. 3a,b) , corroborating the idea that enhanced antigen presentation does not simply reflect bacterial attenuation.
EsxGH Mt impairs priming of naive CD4
+ T cells in vivo. We hypothesized that EsxGH Mt might contribute to impaired priming of CD4 + T cells in vivo. To test this hypothesis, we adoptively transferred carboxyfluorescein succinimidyl ester (CFSE)-labelled P25TCR-Tg colony-forming units (c.f.u.), ΔesxH was cleared from the lungs and failed to disseminate to the draining lymph node. When we used high-dose ΔesxH (10 4 c.f.u.), the bacteria disseminated to the MLNs (Fig. 4a) , although the number of c.f.u. in the lung was much lower than that found in mice infected with 10 2 c.f.u. H37Rv, and there were orders of magnitude fewer ΔesxH mutant in the MLNs than H37Rv at 14 d postinfection. Proliferation of the P25TCR-Tg CD4 + T cells in the MLNs was observed at this time point in response to both ΔesxH and H37Rv (Fig. 4b) , and a similar percentage of P25TCR-Tg CD4 + T cells proliferated in the MLNs and lungs in response to both strains (Fig. 4c) . That this degree of T-cell proliferation occurred in response to orders of magnitude fewer ΔesxH bacilli in the MLNs suggested that ΔesxH-infected cells might be superior to wild-type Mtb-infected cells in priming CD4 + T cells. To compare P25TCRTg CD4 + T-cell responses with equal numbers of wild-type and ΔesxH mutant in vivo, we used intratracheal transfer of infected BMDCs. We adoptively transferred naive CFSElabelled P25TCRTg CD4 + T cells in MHC-II knockout (MHC-II −/− ) mice and compared their activation following intratracheal transfer of MHC-II-expressing (wild-type) BMDCs infected with equal numbers of H37Rv or ΔesxH. This experimental design allowed us to assay the contribution of antigen presentation from the infected DCs and eliminated the possibility that antigen transfer to uninfected bystander DCs was contributing to T-cell priming. Analysis of mediastinal MLNs revealed that, following transfer of DCs infected with ΔesxH, there was a threefold increase in the number of P25TCR-Tg CD4 + T cells (Fig. 5a,b) and five-to six-fold more P25TCR-Tg CD4 + T-cell proliferation (Fig. 5c,d ). This enhanced CD4 + T-cell priming was not due to a higher bacterial burden, as both groups of infected DCs contained similar numbers of bacteria, and equivalent numbers of DCs were transferred into recipient animals (Fig. 5e ). There was also no difference in the number of bacteria in the lungs of the recipient mice (Fig. 5f) . Interestingly, and consistent with the aerosol experiment above, the MLNs contained approximately half as many ΔesxH mutant as wild-type bacteria (Fig. 5g ) but led to a fivefold increase in CD4 + T-cell proliferation. Thus, following transfer of infected DCs, there was more T-cell proliferation in response to fewer ΔesxH than wild-type bacilli. We concluded that EsxH impairs the ability of Mtb-infected DCs to prime CD4 + T cells in vivo.
EsxH protects Mtb from CD4 + T-cell-mediated killing. Direct recognition of infected macrophages is important for CD4 + T cells EsxGH Mt ; the vector control strain was compared with the EsxGH Mt strain for each siRNA treatment. Results are representative of three independent experiments and reflect means ± s.e.m. All significant differences are indicated. For a,b,e-g, IFN-γ released into culture supernatants was measured by an ELISA. *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.0001 (unpaired Student's t-test); NS, not significant.
to control Mtb
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. To determine whether EsxH impairs the ability of effector CD4 + T cells to recognize infected macrophages, we cocultured BMDMs infected with either wild-type Mtb or the ΔesxH mutant with and without P25TCR-Tg CD4 + T cells and plated them to determine the number of c.f.u. We found that the addition of P25TCR-Tg CD4 + T cells to naive or IFN-γ-activated BMDMs had a modest effect on Mtb growth if macrophages were infected with wild-type Mtb (Fig. 6a,b) . In contrast, addition of effector T cells to macrophages infected with the ΔesxH mutant resulted in substantial bacterial killing (Fig. 6a,b) . We concluded that EsxH limits the ability of T cells to promote clearance of Mtb from infected macrophages. The enhanced sensitivity to T cells exhibited by the ΔesxH mutant may also explain why there were fewer ΔesxH than wild-type bacilli in the MLNs in the DC transfer experiments above (Fig. 5g) , while in the lungs ΔesxH and wild type were no different (Fig. 5f ). To test whether EsxH protected Mtb from T-cell-facilitated killing in vivo, we compared the bacterial burden of the ΔesxH mutant in the lungs of C57BL/6 and MHC-II −/− mice, which lack CD4 + T cells. Attenuation of the ΔesxH mutant was ameliorated in MHC-II −/− mice; in wild-type mice, there was more than a 4-log difference in c.f.u. between ΔesxH and wild type. In MHC-II −/− mice, there was a 3-log difference. Although the profound attenuation of the ΔesxH mutant is probably multifactorial, reflecting its role in metal homeostasis, phagosome maturation arrest and potentially other processes, the observation that there was a greater impact of T cells on the ΔesxH mutant than on H37Rv (Fig. 6c) is consistent with the idea that the in vivo attenuation of ΔesxH depends in part on MHC-II-mediated antigen presentation and CD4 + T-cell responses.
Discussion
We showed previously that to promote its intracellular survival Mtb secretes EsxH and inhibits the function of ESCRT. The role of ESCRT in antigen presentation has not previously been established. Here, we 
NATURE MICROBIOLOGY
showed that ESCRT contributes to optimal antigen processing and that Mtb EsxH impairs the activation of CD4 + T cells and their ability to promote bacterial clearance. Macrophages and DCs infected with an Mtb mutant lacking EsxH yielded enhanced T-cell activation, whereas infection with a strain that overexpressed EsxGH Mt elicited diminished T-cell responses. Overexpression of EsxGH Ms , which does not bind HRS or inhibit ESCRT 20 , had no effect on T-cell responses. Thus, the ability of EsxGH Mt to inhibit antigen presentation is probably due to a direct effect on HRS 20 , although additional targets may also play a role. Our findings are in accordance with those of Tufariello et al. 26 who demonstrated an important role of esxH in virulence that is separable from the role in iron acquisition and that cannot be complemented by esxG-esxH from M. smegmatis.
This study is also, to the best of our knowledge, the first demonstration that ESCRT is required for antigen presentation. In DCs, degradation of peptide-loaded MHC-II is regulated by ubiquitination 31, 32 , which has been presumed to be ESCRT dependent. Based on the presumption that ESCRT regulates MHC-II degradation, we expected that ESCRT silencing would result in enhanced MHC-II surface expression and potentially increased antigen presentation. Rather, we found that silencing ESCRT impaired T-cell activation by inhibiting antigen processing and presentation. There are several ways in which ESCRT might do this. First, the multivesicular architecture of the MHC-II compartment might be important for the processing and/or loading of antigen [37] [38] [39] . Alternatively, given the role of ESCRT in phagosome maturation 20, 29 , ESCRT might promote antigen processing because it assists in trafficking Mtb to an acidic phagosomal environment that contains active lysosomal hydrolases. However, the literature does not suggest a simple relationship between phagosome maturation arrest, bacterial fitness and antigen presentation, as some attenuated strains are reported to enhance antigen presentation, whereas others have no effect 10, 11, [40] [41] [42] . Further complicating this explanation is the fact that lysosomal trafficking of Mtb in IFN-γ-activated macrophages does not depend on ESCRT (Supplementary Fig. 2 ). Nonetheless, there may be other aspects of the phagosomal environment that are altered by ESCRT inhibition, an explanation that we favour. For example, ESCRT might be required for trafficking the antigen processing or loading machinery to the phagolysosome or the MHC-II compartment.
Our findings extend well beyond the role of ESCRT in antigen presentation. To the best of our knowledge, this is the first example of an Mtb effector and its corresponding cellular target impairing MHC-II antigen presentation by a mechanism other than Mtb Toll-like receptor 2 agonists blocking IFN-γ signalling. The previously described mechanism cannot explain how Mtb downregulates antigen presentation in antigen-presenting cells that already express MHC-II or in macrophages that are exposed to IFN-γ shortly after they are infected. Here, we have provided a molecular explanation for how, in migratory DCs and IFN-γ-activated macrophages, Mtb blunts T-cell responses. EsxGH Mt may provide a double hit for Mtb by impairing efficient priming of antigen-specific T cells and preventing effector CD4 + T cells from recognizing infected macrophages, which is important for control of Mtb in vivo 36 . Importantly, this mechanism of immune evasion may also undermine the ability of pre-existing CD4 + T cells generated by a vaccine or prior infection to be protective. Our results demonstrated only a partial suppression of T-cell activation in response to ESCRT silencing or esxH expression by the bacilli. Thus, there are likely to be additional mechanisms that Mtb uses to impair antigen presentation.
The observation that EsxGH Mt impairs antigen presentation would seem to be at odds with the findings that EsxG Mt and EsxH Mt , also known as TB9.8 and TB10.4, respectively, are prominent T-cell antigens 43, 44 . This apparent conundrum may be explained by the fact that antigen transfer from infected to uninfected DCs allows priming of T cells in the lymph node 18, 19 . When these T cells arrive in the lung, the EsxGH Mt -imposed block in antigen presentation in infected macrophages would subvert effector responses. This is an important consideration in vaccine candidates that include EsxH; macrophages infected with Mtb expressing abundant EsxH might be those that are imperceptible to CD4 + T cells. Interestingly, a recent study found that EsxA/ESAT-6, secreted by the Esx-1 type VII secretion system, interacts with β 2 -microglobulin and inhibits MHC class I β 2 -microglobulin surface expression 45 . Thus, two of the most dominant T-cell antigens, EsxA and EsxH, appear to undermine the activation of two major T-cell subsets, leading us to speculate that their prominence as T-cell antigens reflects a bacterial strategy to generate an ineffective host response.
In conclusion, we have shown that ESCRT stimulates antigen presentation and that Mtb EsxGH Mt undermines this critical function in activated macrophages and DCs. Our data provide a molecular explanation for the failure of the adaptive immune response to kill Mtb. Recent work has shown that it is possible to identify small molecules that impair type VII secretion 46 . Esx-3 inhibitors could be particularly potent, as inhibiting this system would impair intrinsic bacterial processes involved in metal homeostasis, as well as promoting host clearance by restoring macrophage function and T-cell activation.
Methods
Mice. P25TCR-Tg 30 mice were bred into a C57BL/6 (CD45.1) background. C7TCR-Tg 47 mice have been described previously. C57BL/6 (CD45.2) and MHC-II −/− mice were purchased from The Jackson Laboratory. The New York University School of Medicine Institutional Animal Care and Use Committee approved all work with animals.
Bacterial strains and growth conditions. Mtb H37Rv overexpressing EsxGH Mt 26 have been described previously. Mtb was grown at 37°C to log phase in BD Difco Middlebrook 7H9 (Fisher Scientific) medium with 0.05% Tween 80, BD BBL Middlebrook OADC Enrichment (Fisher Scientific) and 0.2% glycerol. The pJP130 complementing plasmid described below (ΔesxH-compl) and the GFP plasmids were selected with 25 µg ml −1 kanamycin (Sigma). Mycobactin was not used routinely to supplement the mutants during growth in broth culture. When plating for determination of c.f. u., the ΔesxH mutant was grown on 7H10 plates supplemented with 200 ng/ml mycobactin J (Allied Monitor). experiments with at least eight individual replicates per experimental group. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (Student's t-test corrected for multiple comparisons using the Holm-Sidak method). c, C57BL/6 and MHC-II KO mice were infected with H37Rv or ΔesxH by aerosol (10 2 expanded and frozen. After thawing, they were used within the first several passages and not tested for mycoplasma contamination. Bone marrow was isolated from 6-8-week-old male C57BL/6 mice as described previously 49 and cultured in BMMO medium (DMEM with 10% heat-inactivated FBS, 2 mM L-glutamine, 1 mM sodium pyruvate and 20% L929 cell-conditioned medium). BMDMs were collected between 6 and 7 d, detached from plates by incubation in ice-cold PBS with 5 mM EDTA, and then washed and plated in BMMO medium with 10% L929 cell-conditioned medium. Penicillin/streptomycin (Gibco) was added to the medium for passaging but omitted during infections. BMDCs were grown in RPMI 1640 with 10% heatinactivated FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, 1× β-mercaptoethanol (Gibco), 10 mM HEPES and 10 ng ml −1 recombinant murine granulocytemacrophage colony-stimulating factor (Peprotech) for 7 d, followed by sorting of CD11c + DCs using magnetic cell sorting (autoMACS; Miltenyi Biotec).
siRNA treatment. Hiperfect (Qiagen) was used to transfect siRNAs 2 or 3 d before infection of RAW cells or BMDMs, respectively.
CD4
+ T-cell isolation. P25 1, 30 and C7TCR-Tg 47 T H 1 effector cells were generated in vitro as described previously. Briefly, CD4 + T cells were isolated magnetically from lymph node cell suspensions from P25TCR-Tg and C7TCR-Tg mice using microbeads (MACS) and an autoMACS (both from Miltenyi Biotec). The cells were co-cultured with irradiated C57BL/6 splenocytes in the presence of mouse interleukin (IL)-12p70, IL-2, anti-IL-4 neutralizing antibody, and peptide P25 or ESAT-6 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) for 3 d and frozen until used.
Antigen presentation assays. At 7 d after collection, 1 × 10 5 BMDMs per well were plated in 96-well plates and transfected with siRNAs. Two days later, they were treated with 200 U ml −1 IFN-γ (Gibco). The following day, they were infected with a single-cell suspension of Mtb (multiplicity of infection (m.o.i.) of 1-5) prepared as described previously 20 . After 4 h, extracellular bacteria were removed by washing three times with warm PBS. Infected macrophages were incubated at 37°C for an additional 20 h, after which P25TCR T H 1 or C7TCR-Tg CD4 + T cells were added (5 × 10 5 cells per well). At 24 h after co-culture of infected BMDMs with CD4 + T cells, culture supernatants were collected, filtered and assayed for IFN-γ by an enzyme-linked immunosorbent assay (ELISA: BD Biosciences). Alternatively, the antigen presentation assay was performed as above but without knocking down ESCRT, or, instead of infection with live Mtb, BMDMs were incubated with 0.5 µM P25 peptide or 10 µg ml −1 recombinant Ag85B protein (BEI Resources). Antigen presentation assays were also done using BMDCs as antigen-presenting cells. In this case, cells were not treated with IFN-γ before infection.
DQ-OVA processing assay. BMDMs were treated with 50 µg ml −1 DQ-OVA (Molecular Probes) for 30 min at 37°C and washed three times with ice-cold PBS, followed by incubation in fresh medium at 37°C for 24 h, after which they were fixed with 4% paraformaldehyde (PFA). Nuclei were stained with 2.5 µg ml Hoechst 33342 (Molecular Probes). Images were captured using a Nikon Eclipse TiE/B automated fluorescent microscope with a Photometrics HQ@ Monochrome digital camera. Z-stack images were acquired at a magnification of ×60, and the mean fluorescence intensity (fluorescein isothiocyanate) was quantified using NIS-Elements DUO software.
Lysosomal trafficking assay. siRNA-transfected RAW cells or BMDMs were infected with GFP-expressing Mtb for 4 h as described above. One day before infection, macrophages were treated with IFN-γ (100 U ml −1 ) or left untreated. Cells were fixed with 1% PFA in PBS overnight at 24 h postinfection, permeabilized with 0.1% saponin in PBS and blocked with 2% BSA in PBS for 1 h. Cells were then immunostained for LAMP1 (1:1000 dilution; Abcam) for at least 1 h at room temperature or at 4°C overnight, followed by treatment with anti-rabbit Alexa Fluor 594-conjugated secondary antibody (Invitrogen). Images were captured using a Nikon Eclipse TiE/B automated fluorescent microscope described above and analysed using NIS-Elements DUO software as described previously 20 .
Intracellular bacterial growth assay. RAW cells or BMDMs were transfected with siRNA and infected as described above (m.o.i. of 5). IFN-γ (100 U ml Western blot analysis. BMDMs were transfected with siRNA for 72 h, after which cellular lysates were prepared in RIPA buffer with Halt Protease Inhibitor Cocktail (Thermo Scientific) and analysed by western blotting. The antibodies used for western blot analysis were against actin (clone C4; Millipore), HRS (M79; Santa Cruz Biotechnology) and TSG101 (Genetex).
Adoptive transfer and naive P25TCR-Tg CD4 + T-cell proliferation. CD4 + T cells (3 × 10 6 ) collected from the lymph nodes and spleens of female P25TCR-Tg mice (8-12 weeks old) were labelled with 10 µM CFSE for 7 min and adoptively transferred by retro-orbital injections into 8-week-old female recipient mice. After 24 h, recipient mice were infected with 2 × 10 2 c.f.u. H37Rv or 1 × 10 4 c.f.u. ΔesxH mutant by the aerosol route using an Inhalation Exposure Unit (Glas-Col), as described previously 15 . At 7, 14 and 21 d after infection, MLNs and lungs were obtained from recipient mice and cells were analysed for CFSE dilution by flow cytometry. The experiments were not randomized or blinded. The number of animals used was determined based on feasibility and prior experience with the assay. Flow cytometry. BMDMs were fixed in 1% PFA and stained using Alexa Fluor 488-conjugated anti-mouse MHC-II (I-A/I-E, clone M5/114.15.2; Biolegend). Single-cell suspensions from infected lungs and MLNs were stained using the following fluorescently labelled antibodies: Alexa Fluor 700-conjugated anti-mouse CD45.1 antibody (clone A20), peridinin-chlorophyll-conjugated anti-mouse CD3e (clone 145-2C11) and Pacific Blue-conjugated anti-mouse CD4 antibody (clone RM4-5) (all from Biolegend). Flow cytometry was performed using a FACSCalibur and LSR II (BD Biosciences) at the New York University Cytometry and Cell Sorting Core. FlowJo software was used for data analysis.
Plasmids. pJP130 was used to complement the ΔesxH mutant. It was constructed by inserting Rv0289 into pYUB1944, which contains esxG-esxH under control of the hsp60 promoter 26 . Rv0289 was amplified from Mtb genomic DNA by PCR using forward (5′-TAGAAGCTTCTCGCGCTACATGGATGC-3′) and reverse (5′-CCAATCGATTTACGAGGATTGGGTGG-3′) primers, digested with HindIII, and cloned into the HindIII site after Rv0288 in pYUB1944. The addition of Rv0289 to pYUB1944 resulted in enhanced secretion of EsxG and EsxH compared with the parental plasmid.
Mass spectrometry analysis. Triplicate samples of H37Rv and ΔesxH culture filtrate were prepared and analysed by liquid chromatography/tandem mass spectrometry using an Easy nLC-1000 on-line with a QExactive mass spectrometer (Thermo Scientific) as described 26 . The data was analysed with MaxQuant software with the Andromeda search engine for peptide identification. Label-free quantitation algorithms were used to determine normalized relative protein quantitation values 50 .
Statistical analysis. Biological and technical replicates were used for analyses. Data shown are representative of two or more independent experiments. In all figures, error bars indicate means ± s.e.m. An unpaired Student's t-test was used to determine statistical significance between experimental groups unless otherwise indicated.
Data availability. The data that support the findings of this study are available from the corresponding authors (W.R.J. and J.A.P.) on request.
